Skip to Content

Mycophenolate mofetil Disease Interactions

There is 1 disease interaction with mycophenolate mofetil:


Mycophenolate (Includes mycophenolate mofetil) ↔ neutropenia

Severe Potential Hazard, Moderate plausibility. Applies to: Neutropenia

Severe neutropenia has occurred in up to 2% of patients administered mycophenolate. Therapy with mycophenolate should be administered cautiously in patients with or predisposed to neutropenia. Mycophenolate should be discontinued or the dose reduced in patients who develop neutropenia (absolute neutrophil count <1300/mm3). Clinical monitoring of hematopoietic function is recommended. Complete blood counts should be performed weekly during the first month, two times a month during the second and third months, and monthly for the remainder of the first year of treatment.


  1. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, et al "RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection." Ann Surg 216 (1992): 513-8;disc. 518-9
  2. Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG "Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center." Ann Surg 217 (1993): 476-82;disc. 482-4
  3. "Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories, Nutley, NJ.
  4. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG "Mycophenolate mofetil (RS-61443): preclinical, clinical, and three- year experience in heart transplantation." J Heart Lung Transplant 13 (1994): 571-82
  5. Mrozek-Orlowski M, Christie J, Flamme C, Novak J "Pain associated with peripheral infusion of carmustine." Oncol Nurs Forum 18 (1991): 942
View all 5 references

Mycophenolate mofetil drug interactions

There are 260 drug interactions with mycophenolate mofetil

Mycophenolate mofetil alcohol/food interactions

There is 1 alcohol/food interaction with mycophenolate mofetil

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.